Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145

Benzinga Newsdesk www.benzinga.com Positive 86.1%

Neg 0% Neu 0% Pos 86.1%

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $121 to $145.